Gene:
ARRB2
arrestin, beta 2

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1045280 1037C>T, 4226012C>T, 4622638C>T, 786+54C>T, 795C>T, 840C>T, 903C>T, Ser265=, Ser280=, Ser301=
C > T
Not Available
Ser265Ser
No VIP available No Clinical Annotations available VA
rs2036657 *825G>A, *931G>A, 2252G>A, 4228533G>A, 4625159G>A
G > A
3' Flanking
No VIP available No Clinical Annotations available VA
rs34230287 -159C>T, -387C>T, 4217004C>T, 4613630C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs3786047 23+1059A>G, 251+1059A>G, 4218472A>G, 4615098A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4790694 4229728A>C, 4626354A>C
A > C
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  arrestin 3
Alternate Symbols:  BARR2; DKFZp686L0365
PharmGKB Accession Id: PA60

Details

Cytogenetic Location: chr17 : p13.2 - p13.2
GP mRNA Boundary: chr17 : 4613789 - 4624795
GP Gene Boundary: chr17 : 4603789 - 4627795
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Information ?

Curated Information ?

Curated Information ?

Publications related to ARRB2: 10

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
beta-Arrestin2 influences the response to methadone in opioid-dependent patients. The pharmacogenomics journal. 2011. Oneda B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Beta-arrestins 1 and 2 are associated with nicotine dependence in European American smokers. Molecular psychiatry. 2008. Sun D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes, brain, and behavior. 2007. Ikeda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Distinct roles for Src tyrosine kinase in beta2-adrenergic receptor signaling to MAPK and in receptor internalization. The Journal of biological chemistry. 2004. Huang Jianyun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cellular signalling. 2003. Penela Petronila, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. The Biochemical journal. 2003. Shenoy Sudha K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. The Journal of biological chemistry. 2003. Shenoy Sudha K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (New York, N.Y.). 2002. Perry Stephen J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Progress in neurobiology. 2002. Claing Audrey, et al. PubMed

LinkOuts

Entrez Gene:
409
OMIM:
107941
UCSC Genome Browser:
NM_004313
RefSeq RNA:
NM_004313
NM_199004
RefSeq Protein:
NP_004304
NP_945355
RefSeq DNA:
AC_000060
AC_000149
NC_000017
NT_010718
NW_001838403
NW_926584
UniProtKB:
ARRB2_HUMAN (P32121)
Ensembl:
ENSG00000141480
GenAtlas:
ARRB2
GeneCard:
ARRB2
MutDB:
ARRB2
ALFRED:
LO218341T
HuGE:
ARRB2
Comparative Toxicogenomics Database:
409
ModBase:
P32121
HumanCyc Gene:
HS06835
HGNC:
712

Common Searches